Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors
Conditions: Adult Ovarian Granulosa Cell Tumor Interventions: Procedure: Biospecimen Collection; Procedure: Chest Radiography; Procedure: Computed Tomography; Drug: Darolutamide; Drug: Exemestane; Drug: Leuprolide Acetate; Procedure: Magnetic Resonance Imaging; Procedure: Positron Emission Tomography Sponsors: National Cancer Institute (NCI); NRG Oncology Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 13, 2023 Category: Research Source Type: clinical trials
ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors
Conditions: Ovarian Cancer; Recurrent Solid Tumors Interventions: Drug: ZEN003694; Drug: Niraparib Sponsors: Haider Mahdi; GlaxoSmithKline; Zenith Epigenetics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 8, 2023 Category: Research Source Type: clinical trials
Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi
Conditions: Ovarian Cancer; High Grade Serous Adenocarcinoma of Ovary; Primary Peritoneal Carcinoma; Fallopian Tube Cancer Interventions: Drug: Fluzoparib; Drug: Fluzoparib+Apatinib Sponsors: Guangxi Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 7, 2023 Category: Research Source Type: clinical trials
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Solid Cancer Interventions: Drug: R-DXd; Drug: Gemcitabine; Drug: Paclitaxel; Drug: Topotecan; Drug: PLD Sponsors: Daiichi Sankyo, Inc.; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 7, 2023 Category: Research Source Type: clinical trials
HRD Tests for Ovarian cancER
Conditions: Ovarian Cancer Interventions: Genetic: tests to determine HRD status Sponsors: Centre Francois Baclesse Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 1, 2023 Category: Research Source Type: clinical trials
The Effectiveness of an Online Support Group in Enhancing Recovery Identity and Health-Related Quality of Life
Conditions: Ovarian Cancer Interventions: Behavioral: mobile online support group (experiment group); Behavioral: offline support group (control group) Sponsors: Shanghai Jiao Tong University School of Medicine Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 24, 2023 Category: Research Source Type: clinical trials
Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab
Conditions: Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Interventions: Drug: Niraparib Sponsors: Peking University Cancer Hospital& Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 21, 2023 Category: Research Source Type: clinical trials
Combined Program of Supervised Physical Exercise and Nutritional Counseling in Ovarian Cancer Patients on Frontline Maintenance Treatment With PARP Inhibitors
Conditions: Ovarian Cancer Interventions: Procedure: Exercise and dietary recommendations Sponsors: Oncare Madrid; Apices Soluciones S.L. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 18, 2023 Category: Research Source Type: clinical trials
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors
Conditions: Triple Negative Breast Cancer; High Grade Serous Ovarian Cancer; Endometrial Cancer Interventions: Drug: AO-252 Sponsors: A2A Pharmaceuticals Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2023 Category: Research Source Type: clinical trials
Transforming Ovarian Cancer Diagnostic Pathways
Conditions: Ovarian Cancer Sponsors: Professor Sudha Sundar; University of Birmingham Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 13, 2023 Category: Research Source Type: clinical trials
The Registry of Genetic Alterations of Taiwan Ovarian Cancer
Conditions: Ovarian Cancer Sponsors: National Health Research Institutes, Taiwan; National Taiwan University Hospital; Mackay Memorial Hospital; Cathay General Hospital; China Medical University Hospital; Taichung Veterans General Hospital; National Cheng-Kung University Hospital; Chang Gung Medical Foundation; Kaohsiung Veterans General Hospital. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 10, 2023 Category: Research Source Type: clinical trials
New Prognostic Index for Neoadjuvant Chemotherapy Outcome in Patients With Advanced High-grade Serous Ovarian Cancer
Conditions: Ovarian Cancer; Neoadjuvant Chemotherapy; Prognostic Cancer Model Interventions: Diagnostic Test: CRS scoring; Diagnostic Test: Routine blood laboratory testing before treatment Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2023 Category: Research Source Type: clinical trials
Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency
Conditions: Ovarian Cancer Interventions: Drug: Olaparib tablet Sponsors: Alexander B Olawaiye, MD; AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2023 Category: Research Source Type: clinical trials
First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients
Conditions: Carcinoma, Ovarian Epithelial Interventions: Drug: Olaparib; Drug: Bevacizumab Sponsors: Mario Negri Institute for Pharmacological Research; AstraZeneca Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 7, 2023 Category: Research Source Type: clinical trials
Shanghai Ovarian Cancer and Family Care Project
Conditions: Ovarian Cancer Sponsors: Shanghai First Maternity and Infant Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 6, 2023 Category: Research Source Type: clinical trials
